Effect of metformin and pioglitazon in treatment of fatty liver

Comparison of the theraputic effect of pioglitazone and metformin on ultrasound scoring and liver enzymez in potients with non alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023083N2

Enrollment

Registered

2019-09-23

Start date

2019-05-18

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: the first group received pioglitazone 30 mg for 6 months. Intervention 2: Intervention group: second group received metformin 1 gr and VitE 800 for 6 months.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age range 18_65 years old Patients based on ultrasound evidence and testing of non-alcoholic fatty liver

Exclusion criteria

Exclusion criteria: People under the age of 18 Pregnant and lactating women People with kidney failure 30> GFR People with heart failure HF Class 3 and 4 People with liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Serum Spartate Aminotransferase Level. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.;Grade sonography. Timepoint: On arrival and after intervention. Method of measurement: Ultrasound machine.;Serum levels of alanine amino transferase. Timepoint: On arrival and after intervention. Method of measurement: Laboratory methods with Kits.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Haleh Rezaee

Tabriz University of Medical Sciences

rezaeeha@tbzmed.ac.ir+98 41 3337 2250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026